Ambrisentan | 安倍生坦 | MedChemExpress (MCE)

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ambrisentan

CAS No. : 177036-94-1

MCE 国际站：Ambrisentan

产品活性：Ambrisentan 是一种选择性的ET A型受体 (ETAR) 拮抗剂。

研究领域：GPCR/G Protein

作用靶点：Endothelin Receptor

In Vitro: Ambrisentan is an endothelin type A receptor antagonist. Ambrisentan induces Nrf2 activation. Endothelial permeability increased in BMEC monolayers at 24 h of hypoxia exposure and compared to vehicle control, Ambrisentan attenuates hypoxia-induced BMEC leak. These results are reversed when prior to treatment BMEC are transfected with siRNA against Nrf2.

In Vivo: In the Ambrisentan group, hepatic hydroxyproline content is significantly lower than in the control group (18.0 μg/g±6.1 μg/g vs 33.9 μg/g±13.5 μg/g liver, respectively, P=0.014). Hepatic fibrosis estimated by Sirius red staining and areas positive for α-smooth muscle actin, indicative of activated hepatic stellate cells, are also significantly lower in the Ambrisentan group (0.46%±0.18% vs 1.11%±0.28%, respectively, P=0.0003; and 0.12%±0.08% vs 0.25%±0.11%, respectively, P=0.047). Moreover, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1 (TIMP-1) are significantly lower by 60% and 45%, respectively, in the Ambrisentan group. Inflammation, steatosis, and endothelin-related mRNA expression in the liver are not significantly different between the groups. Ambrisentan attenuates the progression of hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing procollagen-1 and TIMP-1 gene expression. Ambrisentan did not affect inflammation or steatosis.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Coagulation and Anti-coagulation Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Endothelin 1 (swine, human)  |  Bosentan  |  Macitentan  |  BQ-788  |  Atrasentan hydrochloride  |  BQ-123  |  Carperitide acetate  |  Endothelin-3, human, mouse, rabbit, rat TFA  |  Sulfisoxazole  |  Atrial Natriuretic Peptide (ANP) (1-28), rat  |  Sitaxsentan sodium  |  Sparsentan  |  Zibotentan  |  A-192621  |  Clazosentan  |  IRL-1620 TFA  |  Aprocitentan  |  Nebentan potassium  |  Darusentan  |  Tezosentan  |  Avosentan  |  IRL 2500  |  Ro 46-8443  |  BMS 182874

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。